
Lilly to buy Calytrix Bio for up to $1.5 billion
来源:Reuters发布于 2026-11-16
Eli Lilly has agreed to acquire Calytrix Bio for up to $1.5 billion in cash to expand the development of treatments for rare blood cancers, the privately held biotech said on Monday.
相关标的:LLY
本文内容来自外部来源,点击「继续访问」将跳转到原始发布站点。